Yuanzhen Su

419 total citations
11 papers, 345 citations indexed

About

Yuanzhen Su is a scholar working on Biomedical Engineering, Molecular Biology and Biomaterials. According to data from OpenAlex, Yuanzhen Su has authored 11 papers receiving a total of 345 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Biomedical Engineering, 4 papers in Molecular Biology and 4 papers in Biomaterials. Recurrent topics in Yuanzhen Su's work include Nanoplatforms for cancer theranostics (7 papers), Nanoparticle-Based Drug Delivery (4 papers) and Immunotherapy and Immune Responses (3 papers). Yuanzhen Su is often cited by papers focused on Nanoplatforms for cancer theranostics (7 papers), Nanoparticle-Based Drug Delivery (4 papers) and Immunotherapy and Immune Responses (3 papers). Yuanzhen Su collaborates with scholars based in China, United States and Russia. Yuanzhen Su's co-authors include Jianxun Ding, Xuesi Chen, Du Zhi, Lingzhu Zhao, Yanyu Qu, Jie Du, Yan Mo, Feng Yu, Xiaobo Jia and Yong Chen and has published in prestigious journals such as Advanced Materials, SHILAP Revista de lepidopterología and Nano Letters.

In The Last Decade

Yuanzhen Su

10 papers receiving 344 citations

Peers

Yuanzhen Su

BE

EEE

BIOMA

MB

IMMUN

Ziyan Xu China

Lingxiao Xie United States

Jingxuan Yan China

Shuaishuai Liu China

Wei‐Han Lin Taiwan

Jinming Yu China

Myunggi An United States

Ria D. Corder United States

Yu Xiong China

Tianxu Fang China

Ziyan Xu China

Yuanzhen Su

168 ×1.4

BE

45 ×0.4

EEE

62 ×0.7

BIOMA

57 ×0.7

MB

35 ×0.6

IMMUN

Citations per year, relative to Yuanzhen Su Yuanzhen Su (= 1×) peers Ziyan Xu

Countries citing papers authored by Yuanzhen Su

Since Specialization

Citations

This map shows the geographic impact of Yuanzhen Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuanzhen Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuanzhen Su more than expected).

Fields of papers citing papers by Yuanzhen Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuanzhen Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuanzhen Su. The network helps show where Yuanzhen Su may publish in the future.

Co-authorship network of co-authors of Yuanzhen Su

This figure shows the co-authorship network connecting the top 25 collaborators of Yuanzhen Su. A scholar is included among the top collaborators of Yuanzhen Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuanzhen Su. Yuanzhen Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Su, Yuanzhen, et al.. (2025). Unimolecular chiral poly(amino acid)s as adjuvants of nanovaccines for augmented cancer immunotherapy. Chinese Chemical Letters. 36(11). 111477–111477. 2 indexed citations

2.

Yang, Zhaofan, Yuanzhen Su, Hao Liu, et al.. (2025). Prodrug-designed nanocarrier co-delivering chemotherapeutic and vascular disrupting agents with exceptionally high drug loading capacity. Journal of Controlled Release. 382. 113628–113628. 2 indexed citations

3.

Yang, Zhaofan, Yuanzhen Su, Hao Liu, et al.. (2025). Polymeric Nanoparticles Simultaneously Delivering Paclitaxel Prodrug and Combretastatin A4 with Exceptionally High Drug Loading for Cancer Combination Therapy. Nano Letters. 25(9). 3479–3488. 8 indexed citations

4.

Liu, Hao, Zi Mei, Sheng Ma, et al.. (2024). Polymeric immunogel prevents tumor recurrence and metastasis by dual activation of innate and adaptive immunity. Bioactive Materials. 45. 102–114.

5.

Su, Yuanzhen, et al.. (2023). Chiral polypeptide nanoparticles as nanoadjuvants of nanovaccines for efficient cancer prevention and therapy. Science Bulletin. 68(3). 284–294. 51 indexed citations

6.

Su, Yuanzhen, et al.. (2023). Development of stimuli responsive polymeric nanomedicines modulating tumor microenvironment for improved cancer therapy. SHILAP Revista de lepidopterología. 3(1). 4–30. 8 indexed citations

7.

Xu, Weiguo, Yuanzhen Su, Jia-Zhen Yang, et al.. (2023). Immunologically effective poly(D-lactic acid) nanoparticle enhances anticancer immune response. Science China Chemistry. 66(4). 1150–1160. 33 indexed citations

8.

Tan, Wenxi, et al.. (2022). Aptamer Nanomaterials for Ovarian Cancer Target Theranostics. Frontiers in Bioengineering and Biotechnology. 10. 884405–884405. 17 indexed citations

9.

Liu, Yang, Zhongyu Jiang, Yifu Sun, et al.. (2022). Acidity‐Triggered Transformable Polypeptide Self‐Assembly to Initiate Tumor‐Specific Biomineralization. Advanced Materials. 35(15). 2203291–2203291. 44 indexed citations

10.

Qi, Wei, et al.. (2021). Immunologically Effective Biomaterials. ACS Applied Materials & Interfaces. 13(48). 56719–56724. 51 indexed citations

11.

Zhi, Du, Yuanzhen Su, Yanyu Qu, et al.. (2019). A mechanically robust, biodegradable and high performance cellulose gel membrane as gel polymer electrolyte of lithium-ion battery. Electrochimica Acta. 299. 19–26. 129 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact